Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety CAMBRIDGE, ...

That deal gave Novartis a minority stake in Anthos, which went on to advance the drug into Phase 3 testing. Abelacimab is a new type of anticoagulant called a Factor XI inhibitor. It’s designed to be ...

Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture ...

Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

Varun Chakravarthy was brought in as a last-minute replacement in the Champions Trophy 2025 India squad in place of Yashasvi ...

Bayer is in a race in the Factor XI inhibitor category with other developers, including Bristol-Myers Squibb and Johnson & Johnson with milvexian – also in a phase 3 programme called LIBREXIA ...